Abstract
Background V-1 Immunitor (V1) is a therapeutic AIDS vaccine formulated as an oral pill comprising heat-inactivated HIV antigens derived from pooled blood of HIV-positive donors. Several studies carried out in Thailand have reported beneficial effects of V1 in AIDS patients including the increase in CD4 counts; decrease in viral load; body weight gain; improved clinical symptoms; and extended survival. The goal of our study was to substantiate these effects independently in another country.
Highlights
V-1 Immunitor (V1) is a therapeutic AIDS vaccine formulated as an oral pill comprising heat-inactivated HIV antigens derived from pooled blood of HIV-positive donors
Several studies carried out in Thailand have reported beneficial effects of V1 in AIDS patients including the increase in CD4 counts; decrease in viral load; body weight gain; improved clinical symptoms; and extended survival
Increase in CD4 counts and decrease in viral load can serve as immune correlates of vaccine efficacy in other AIDS vaccine clinical trials
Summary
Pilot trial of oral therapeutic HIV vaccine, V-1 Immunitor, on HIV and HIV/HCV patients in Russia. Aldar Bourinbaiar*, Vladimir Orlovsky, Vichai Jirathitikal, Orapun Metadilogkul, Popov Dmitry. From 16th International Symposium on HIV and Emerging Infectious Diseases Marseille, France. From 16th International Symposium on HIV and Emerging Infectious Diseases Marseille, France. 24-26 March 2010
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
